S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:ABUS

Arbutus Biopharma Stock Forecast, Price & News

$3.13
-0.06 (-1.88%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.07
$3.21
50-Day Range
$3.11
$4.62
52-Week Range
$2.43
$5.87
Volume
652,962 shs
Average Volume
2.09 million shs
Market Capitalization
$423.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.55
30 days | 90 days | 365 days | Advanced Chart
Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.


Arbutus Biopharma logo

About Arbutus Biopharma

Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Headlines

Arbutus Biopharma (NASDAQ:ABUS) Rating Reiterated by HC Wainwright
November 8, 2021 |  americanbankingnews.com
Arbutus Biopharma (NASDAQ:ABUS) Issues Earnings Results
November 5, 2021 |  americanbankingnews.com
Arbutus Biopharma (ABUS) Q3 2021 Earnings Call Transcript
November 5, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABUS
Employees
77
Year Founded
1992

Sales & Book Value

Annual Sales
$6.91 million
Book Value
($0.23) per share

Profitability

Net Income
$-63.74 million
Net Margins
-707.79%
Pretax Margin
-707.79%

Debt

Price-To-Earnings

Miscellaneous

Free Float
124,989,000
Market Cap
$423.39 million
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
11/27/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/03/2022

Social Links


MarketRank

Overall MarketRank

2.10 out of 5 stars

Medical Sector

488th out of 1,391 stocks

Pharmaceutical Preparations Industry

227th out of 669 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

Is Arbutus Biopharma a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arbutus Biopharma stock.
View analyst ratings for Arbutus Biopharma
or view top-rated stocks.

How has Arbutus Biopharma's stock price been impacted by Coronavirus (COVID-19)?

Arbutus Biopharma's stock was trading at $2.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABUS shares have increased by 21.3% and is now trading at $3.13.
View which stocks have been most impacted by COVID-19
.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Arbutus Biopharma
.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) posted its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, meeting the consensus estimate of ($0.24). The biopharmaceutical company earned $3.34 million during the quarter, compared to analyst estimates of $2.36 million. During the same period last year, the firm earned ($0.27) earnings per share.
View Arbutus Biopharma's earnings history
.

What price target have analysts set for ABUS?

5 analysts have issued 12 month target prices for Arbutus Biopharma's stock. Their forecasts range from $5.00 to $9.00. On average, they anticipate Arbutus Biopharma's stock price to reach $7.25 in the next year. This suggests a possible upside of 131.6% from the stock's current price.
View analysts' price targets for Arbutus Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the following people:
  • William H. Collier, President, Chief Executive Officer & Director
  • David C. Hastings, Chief Financial & Accounting Officer
  • Michael J. Sofia, Chief Scientific Officer
  • Elizabeth Howard, Secretary, Chief Compliance Officer & EVP
  • Michael J. McElhaugh, Chief Business Officer

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma CEO Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among Arbutus Biopharma's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.99%), RTW Investments LP (4.77%), Geode Capital Management LLC (1.55%), Advisor Group Holdings Inc. (1.38%), Point72 Asset Management L.P. (0.90%) and Two Sigma Investments LP (0.74%).
View institutional ownership trends for Arbutus Biopharma
.

Which major investors are selling Arbutus Biopharma stock?

ABUS stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Deutsche Bank AG, Cowen AND Company LLC, Two Sigma Advisers LP, Point72 Asset Management L.P., Citadel Advisors LLC, Morgan Stanley, and California State Teachers Retirement System.
View insider buying and selling activity for Arbutus Biopharma
or view top insider-selling stocks.

Which major investors are buying Arbutus Biopharma stock?

ABUS stock was purchased by a variety of institutional investors in the last quarter, including Barclays PLC, SG Americas Securities LLC, Two Sigma Investments LP, Marshall Wace LLP, Geode Capital Management LLC, Goldman Sachs Group Inc., Schonfeld Strategic Advisors LLC, and Jane Street Group LLC.
View insider buying and selling activity for Arbutus Biopharma
or or view top insider-buying stocks.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $3.13.

How much money does Arbutus Biopharma make?

Arbutus Biopharma has a market capitalization of $423.39 million and generates $6.91 million in revenue each year. The biopharmaceutical company earns $-63.74 million in net income (profit) each year or ($0.91) on an earnings per share basis.

How many employees does Arbutus Biopharma have?

Arbutus Biopharma employs 77 workers across the globe.

When was Arbutus Biopharma founded?

Arbutus Biopharma was founded in 1992.

What is Arbutus Biopharma's official website?

The official website for Arbutus Biopharma is www.arbutusbio.com.

Where are Arbutus Biopharma's headquarters?

Arbutus Biopharma is headquartered at 701 VETERANS CIRCLE, WARMINSTER PA, 18974.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The biopharmaceutical company can be reached via phone at (267) 469-0914, via email at [email protected], or via fax at 604-419-3201.


This page was last updated on 11/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.